Cyclo Therapeutics- Warrants (14/11/2025) Return on Equity

Cyclo Therapeutics- Warrants (14/11/2025) (CYTHW) currently reports a ROE of 184.06%. That is above the Healthcare sector average of 22.01%. Use the charts on this page to explore Cyclo Therapeutics- Warrants (14/11/2025)'s ROE history and peer comparisons.

Cyclo Therapeutics- Warrants (14/11/2025)'s ROE of 184.06% is higher than the Healthcare sector average of 22.01%. That is roughly 736.3% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Cyclo Therapeutics- Warrants (14/11/2025)'s current 184.06% should be judged against Healthcare norms (sector average: 22.01%) and against CYTHW's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 184.06%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.01%. From there, open related valuation or income-statement pages for Cyclo Therapeutics- Warrants (14/11/2025), and consider following CYTHW for alerts when major investors trade the stock.

Cyclo Therapeutics- Warrants (14/11/2025) is classified in the Healthcare sector. On ROE, it currently shows 184.06% versus a sector average near 22.01%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CYTHW with unrelated industries.